You are here: Home » PTI Stories » National » News
Business Standard

Lupin gets USFDA nod for chemotherapy-associated nausea and vomiting injection

Topics
Health Medical Pharma

Press Trust of India  |  New Delhi 

Drug firm Lupin on Friday said it has received approval from the US health regulator for its generic Fosaprepitant for injection, which is used to prevent nausea and vomiting associated with cancer chemotherapy.

The company has received approval from the United States Food and Drug Administration (USFDA) for its Fosaprepitant for injection, 150 mg single-dose vial, Lupin said in a statement.

The product is a generic version of Merck Sharp & Dohme Corp's Emend for injection in the same strength, it added.

According to IQVIA MAT June 2019 data, Fosaprepitant for injection, 150 mg single-dose vial, had a total annual sale of around USD 285 million in the US, Lupin said.

The drug is indicated for adults in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin, it added.

It is also used for prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy in adults, Lupin said.

Shares of Lupin on Friday closed at Rs 772.25 per scrip on the BSE, up 0.88 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, September 06 2019. 15:45 IST
RECOMMENDED FOR YOU